Initial treatment of allergic rhinitis (AR) depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).1
H1-ANTIHISTAMINES — Oral second-generation H1-antihistamines (see Table 2) are effective for initial treatment of the nasal symptoms of AR (itching, sneezing, rhinorrhea). They can also reduce ocular symptoms (itching, tearing, redness).
Oral first-generation H1-antihistamines...
RELEASE
The FDA has approved changes to the labeling of Sublocade (Indivior), an extended-release formulation of the partial opioid agonist buprenorphine, to permit faster initiation and use of alternative injection sites. Sublocade is indicated for once-monthly subcutaneous treatment of moderate to severe opioid use disorder.1
Buprenorphine is the maintenance treatment of choice for most patients with opioid use disorder. To prevent severe opioid withdrawal, patients must already be receiving treatment with buprenorphine or undergo a trial with a short-acting transmucosal product before a long-acting formulation can be initiated.2 The labeling changes allow for a first subcutaneous dose of Sublocade to be given after a single transmucosal test dose of buprenorphine; previously, use of transmucosal buprenorphine for at least 7 days had been …